<DOC>
	<DOCNO>NCT00611754</DOCNO>
	<brief_summary>To evaluate efficacy first line oxaliplatin combination 5-fluorouracil ( 5-FU ) patient advance inoperable metastatic head neck cancer investigate safety profile regimen indication consider criterion efficacy ( clinical benefit , survival )</brief_summary>
	<brief_title>Phase II Study Oxaliplatin Combination With 5-Fu 1st Line Treatment Locally Advanced Metastatic Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Patients age 1870 year , inoperable locally advanced metastatic squamous cell carcinoma head neck ( stage IIIIV ) histologically proven , prior chemo and/or hormone therapy metastatic disease local recurrence ( adjuvant neoadjuvant chemotherapy radiochemotherapy allow finish since 6 month inclusion cisplatinum total dose use &lt; or=to 300 mg/m² carboplatinum total dose use &lt; or=to 200mg/m² ) , least 1 target lesion ( measurable 2 dimension &gt; or=to 20 mm compute tomography ( CT ) magnetic resonance imaging ( MRI ) evaluate &lt; 15 day start study treatment , outside irradiated field ) , performance status ( PS ) &lt; =to 2 World Health Organization ( WHO ) , weight loss &lt; 5 % normal weight , hemoglobin &gt; =to 10 g/dL , neutrophils &gt; =to 2000/mm3 , platelet &gt; =to 100,000/mm3 , creatinine &lt; =to 1.5 x upper limit normal ( ULN ) , bilirubin &lt; =to .5 x ULN , alanine aminotransferase ( ALT ) /aspartate aminotransferase ( AST ) &lt; =to 2.5 x ULN ( 5 x ULN liver metastasis ) , clot : prothrombin time ( PT ) &gt; =to 60 % . Written inform consent sign patient doctor prior study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>